Analyses of patients treated with atezolizumab plus bevacizumab in the GO30140 arm A cohort showed that responders (CR/PR) had a higher density of infiltrating CD8+ T cells, CD3+ T cells, and GZMB+CD3+ T cells in tumor areas than non-responders (SD/PD) (p = 0.007, p = 0.039, and p = 0.044, respectively). Here, CD8A is linked to neoplasm.